What Happened
- The Maharashtra government launched a statewide HPV (Human Papillomavirus) vaccination campaign on March 8, 2026 — International Women's Day — targeting approximately 8.94 lakh adolescent girls aged 14–15 years across the state.
- In Mumbai alone, 1,30,000 girls will receive the vaccine; the first phase covers 24,936 students from BMC-run schools, with private and government-aided schools included in subsequent phases.
- Maharashtra's drive is part of the nationwide HPV vaccination programme launched by Prime Minister Narendra Modi on February 28, 2026, from Ajmer, Rajasthan — offering free immunisation to approximately 1.15 crore girls aged 14 at government facilities across all states and UTs.
- The vaccine being administered is Gardasil-4 (quadrivalent HPV vaccine), offered as a single dose at government health facilities.
- The vaccination is voluntary with mandatory parental consent; all registration and certificate issuance is conducted digitally through the Central Government's U-WIN (Universal Immunisation Wing) portal.
- Maharashtra has supplied 20,160 doses to the Brihanmumbai Municipal Corporation (BMC) for the initial rollout phase.
Static Topic Bridges
Human Papillomavirus (HPV) and Cervical Cancer
Human Papillomavirus (HPV) is a group of over 200 related viruses, transmitted primarily through skin-to-skin or sexual contact. Persistent infection with high-risk HPV strains — particularly types 16 and 18 — is responsible for approximately 70% of all cervical cancer cases globally and over 80% of cases in India. HPV types 16 and 18 are also linked to other anogenital cancers and oropharyngeal cancers. Most HPV infections are transient and clear on their own; cervical cancer develops only in a small fraction of women with persistent high-risk HPV infection.
- HPV types 16 and 18: account for ~70% of global cervical cancer and >80% of cases in India
- High-risk HPV types (also include 31, 33, 45, 52, 58): classified by the International Agency for Research on Cancer (IARC) as Group 1 carcinogens
- Natural history: HPV infection → persistent infection in some women → precancerous cervical lesions (CIN 1/2/3) → invasive cervical cancer (typically over 10–20 years)
- Window for vaccination: most effective before first sexual contact; WHO recommends vaccination at ages 9–14
- India's dominant vaccine in National Programme: Gardasil-4 (protects against HPV types 6, 11, 16, 18); Gardasil-9 and Cervarix are also licensed in India
- Indigenous option: Cervavac (manufactured by Serum Institute of India) — a bivalent HPV vaccine targeting types 16 and 18, approved by CDSCO in 2022
Connection to this news: Maharashtra's campaign specifically targets the age group (14–15 years) where vaccination is most effective — before likely HPV exposure — aligning with both WHO guidance and India's national programme design.
Universal Immunisation Programme (UIP) and HPV Integration
India's Universal Immunisation Programme (UIP), launched in 1985 under the National Health Mission (NHM), is one of the largest public health initiatives in the world, reaching approximately 2.67 crore infants annually. It provides free vaccines against 12 vaccine-preventable diseases at government facilities. Until 2026, HPV vaccination was not part of the national schedule, as it was only piloted in select states (a demonstration project in Andhra Pradesh and Gujarat in 2009–10 faced controversy). The inclusion of HPV vaccine into the national immunisation calendar in 2026 marks a significant policy shift.
- UIP currently covers: BCG, OPV, IPV, Pentavalent (DPT+HepB+Hib), Rotavirus vaccine, PCV, Measles-Rubella (MR), JE vaccine (endemic districts), Td booster
- HPV vaccine addition: first adolescent vaccine to be universally included in India's national schedule
- Target cohort: ~1.15 crore 14-year-old girls per year (nationwide)
- Platform: U-WIN (Universal Immunisation Wing) portal — digital registration, consent management, and certificate issuance
- Delivery model: school-based (primary) + government health facilities (supplementary)
- Dosing: single dose for girls aged 9–14 years (per WHO/NTAGI revised guidance for this age group)
Connection to this news: Maharashtra's rollout is the state-level execution of the newly expanded national programme, using the UIP delivery infrastructure (government health facilities, ASHA workers, BMC health teams) to reach adolescent girls.
WHO 90-70-90 Cervical Cancer Elimination Strategy
The World Health Organisation (WHO) launched a global strategy in 2020 to eliminate cervical cancer as a public health problem by 2030, built around three targets known as the 90-70-90 strategy. These targets set benchmarks for vaccination, screening, and treatment coverage that, if achieved, would reduce cervical cancer incidence to below 4 cases per 100,000 women — the WHO threshold for elimination.
- Target 1 (90): 90% of girls fully vaccinated with HPV vaccine by age 15
- Target 2 (70): 70% of women screened with a high-performance test by age 35, and again by 45
- Target 3 (90): 90% of women with cervical disease receiving appropriate treatment
- India's current gap: vaccination coverage for HPV was near-zero before 2026 at the national level; screening coverage is estimated below 30% nationally
- Cervical cancer rank: second most common cancer among women in India (after breast cancer)
- Modelling estimates: achieving 90-70-90 globally could avert 74 million new cases of cervical cancer and prevent 62 million deaths by 2120
Connection to this news: India's 2026 national programme launch, with Maharashtra's Women's Day rollout as a flagship state execution, is the country's most concrete step yet toward meeting WHO's Target 1 — vaccinating 90% of eligible girls — and reorienting national health policy toward cervical cancer elimination.
Key Facts & Data
- Maharashtra target: 8.94 lakh girls aged 14–15 years
- Mumbai first-phase target: 24,936 students from BMC schools; 1,30,000 total in Mumbai
- Vaccine: Gardasil-4 (quadrivalent; covers HPV types 6, 11, 16, 18)
- Dosing schedule: single dose for girls aged 9–14 (revised WHO/NTAGI guidance)
- National programme launch: February 28, 2026, Ajmer — PM Modi
- National target: ~1.15 crore 14-year-old girls annually, free at government facilities
- Registration platform: U-WIN (Universal Immunisation Wing) portal
- Maharashtra initial dose supply to BMC: 20,160 doses
- Cervical cancer deaths in India annually: ~74,000
- HPV types causing 80%+ of India's cervical cancer: 16 and 18
- WHO elimination threshold: <4 cases per 100,000 women per year